LUZHU BIOTECH-B(02480)

25.350+0.0000.00%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- CEO Jian Kong, Beijing Luzhu Biotechnology Co., Ltd.'s (HKG:2480) largest shareholder sees value of holdings go down 9.5% after recent drop
  Simply Wall St. · 02-14
  CEO Jian Kong, Beijing Luzhu Biotechnology Co., Ltd.'s (HKG:2480) largest shareholder sees value of holdings go down 9.5% after recent drop
- Beijing Luzhu Biotechnology's License Application for Herpes Zoster Vaccine Accepted by Chinese Regulator
  MT Newswires Live · 02-10
  Beijing Luzhu Biotechnology's License Application for Herpes Zoster Vaccine Accepted by Chinese Regulator
- Beijing Luzhu Biotechnology Secures Bank Loan Facilities of Up to 300 Million Yuan
  MT Newswires Live · 2024-12-12
  Beijing Luzhu Biotechnology Secures Bank Loan Facilities of Up to 300 Million Yuan
- BRIEF-Beijing Luzhu Biotechnology Enters Facility Agreements With Commercial Banks For RMB570.0 Mln
  Reuters · 2024-12-12
  BRIEF-Beijing Luzhu Biotechnology Enters Facility Agreements With Commercial Banks For RMB570.0 Mln
- Beijing Luzhu Biotechnology - Facility Agreements With Commercial Banks for RMB570.0 Mln of Bank Facilities
  THOMSON REUTERS · 2024-12-12
  Beijing Luzhu Biotechnology - Facility Agreements With Commercial Banks for RMB570.0 Mln of Bank Facilities
- After the recent decline, Beijing Luzhu Biotechnology Co., Ltd. (HKG:2480) CEO Jian Kong's holdings have lost 8.6% of their value
  Simply Wall St. · 2024-10-27
  After the recent decline, Beijing Luzhu Biotechnology Co., Ltd. (HKG:2480) CEO Jian Kong's holdings have lost 8.6% of their value
Company Profile
Company Name
LUZHU BIOTECH-B
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://luzhubiotech.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Beijing Luzhu Biotechnology Co Ltd is a China-based company principally engaged in drug discovery, research and development and commercialization. The Company is also engaged in out-licensing human vaccines and therapeutic biologics. Its products under clinical development include recombinant herpes zoster vaccine LZ901, and antibody injection products K3 and K193. Its LZ901 is mainly used to prevent herpes zoster caused by varicella zoster virus in adults aged 50 and above. The Company operates in the domestic market and overseas markets.